NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts' consensus estimates of ($2.40) by $1.14. The biopharmaceutical company earned $3.46 million during the quarter, compared to the consensus estimate of $2 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.04% and a negative net margin of 26.80%. View GW Pharmaceuticals PLC-'s Earnings History.

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

12 equities research analysts have issued 1-year price targets for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $134.00 to $260.00. On average, they anticipate GW Pharmaceuticals PLC-'s share price to reach $204.36 in the next year. This suggests a possible upside of 62.6% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

News coverage about GWPH stock has been trending very negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,230,000 shares, an increase of 8.9% from the January 15th total of 5,720,000 shares. Based on an average daily trading volume, of 740,100 shares, the short-interest ratio is presently 8.4 days. Currently, 20.3% of the shares of the company are sold short. View GW Pharmaceuticals PLC-'s Current Options Chain.

Some companies that are related to GW Pharmaceuticals PLC- include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ) and Dr.Reddy's Laboratories (RDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Walt Disney (DIS) and Zynerba Pharmaceuticals (ZYNE).

GW Pharmaceuticals PLC-'s stock is owned by many different of retail and institutional investors. Top institutional investors include Capital Research Global Investors (11.73%), Franklin Resources Inc. (7.42%), Capital World Investors (3.58%), Victory Capital Management Inc. (3.15%), Victory Capital Management Inc. (3.15%) and Janus Henderson Group PLC (2.94%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Lord Abbett & CO. LLC, Credit Suisse AG, Renaissance Technologies LLC, Marshall Wace LLP, DekaBank Deutsche Girozentrale, Schonfeld Strategic Advisors LLC and Redwood Investments LLC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

GWPH stock was acquired by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Franklin Resources Inc., Janus Henderson Group PLC, Eventide Asset Management LLC, Capital World Investors, Fred Alger Management LLC, Parkman Healthcare Partners LLC and Marshall Wace North America L.P.. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $125.69.

GW Pharmaceuticals PLC- has a market capitalization of $3.88 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-79,880,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]